QQ客服 官方微博 反馈留言

	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
	Zhou, Caicun*; Wu, Yi-Long; Chen, Gongyan; Liu, Xiaoqing; Zhu, Yunzhong; Lu, Shun; Feng, Jifeng; He, Jianxing; Han, Baohui; Wang, Jie
刊名	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
	2015
卷号	33期号:19页码:2197-U108
ISSN号	0732-183X
DOI	10.1200/JCO.2014.59.4424
URL标识	查看原文
WOS记录号	WOS:000361630500012
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3315038
专题	中南大学
作者单位	[Zhou, Caicun] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China.
推荐引用方式 GB/T 7714	Zhou, Caicun*,Wu, Yi-Long,Chen, Gongyan,et al. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2015,33(19):2197-U108.
APA	Zhou, Caicun*.,Wu, Yi-Long.,Chen, Gongyan.,Liu, Xiaoqing.,Zhu, Yunzhong.,...&Yin, Anny-Yue.(2015).BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer..Journal of clinical oncology : official journal of the American Society of Clinical Oncology,33(19),2197-U108.
MLA	Zhou, Caicun*,et al."BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.".Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33.19(2015):2197-U108.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。